Related Experiment Video
Updated: Jun 8, 2025

Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment
Francesca Nicolardi1, Federica Corona2, Laura Badina3
1University of Trieste, Trieste, Italy. francesca.nic94@gmail.com.
Abstract:
Oral immunotherapy is proposed as the only active intervention to modify allergies and decrease the risk of severe reactions. However, it is crucial to note that oral immunotherapy still presents a notable failure rate and potential for severe, life-threatening outcomes. Notably, patients who discontinue oral immunotherapy may face an increased risk of fatal reactions. Omalizumab could be a viable option for patients with failed oral immunotherapy.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Allergic Reactions
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Cross-reactivity
Allergic Drug Reactions
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:

